A250516P95000
- 0.33
- +0.18+120.00%
Agilent Technologies Newsroom
Trending Industry Today: Vertex Pharmaceuticals Leads Losses In Gene Editing Stocks
Bernstein Maintains Agilent Technologies(A.US) With Hold Rating
Why Agilent Technologies, Inc. (NYSE:A) Could Be Worth Watching
Agilent Unveils Transformative Seahorse XF Flex Analyzer: Revolutionizing 3D Tissue and Organoid Research
SMITH (A.O Earnings Results: $AOS Reports Quarterly Earnings
Agilent Technologies (NYSE:A) Has A Rock Solid Balance Sheet
Live Cell Imaging Market Worth US$4.75 Billion in 2030 With 8.68% CAGR | MarketsandMarkets
Smackover Lithium's South West Arkansas Project Receives Unanimous Vote of Approval to Establish the Phase I Brine Production Unit From the Arkansas Oil and Gas Commission
Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025
Antelope Enterprise Regains Compliance With Nasdaq
New Analyst Forecast: $A Given $116.0 Price Target
Jefferies Maintains Agilent Technologies(A.US) With Hold Rating, Cuts Target Price to $116
Agilent Is Maintained at Hold by Jefferies
Express News | Agilent Technologies Inc : Jefferies Cuts Target Price to $116.00 From $135.00
With 90% Institutional Ownership, Agilent Technologies, Inc. (NYSE:A) Is a Favorite Amongst the Big Guns
Leerink Partners Maintains Agilent Technologies(A.US) With Buy Rating, Cuts Target Price to $125
Wells Fargo Maintains Agilent Technologies(A.US) With Buy Rating, Cuts Target Price to $135
Agilent Is Maintained at Overweight by Wells Fargo
Agilent Technologies Gets European Certification For PD-L1 IHC 22C3 PharmDx To Help Gastric Or GEJ Adenocarcinoma Patients for KEYTRUDA Therapy
Express News | Agilent Technologies Inc - Receives European Ivdr Certification for Pd-L1 Ihc 22C3 Pharmdx